Share Price and Basic Stock Data
Last Updated: October 22, 2025, 8:45 am
PEG Ratio | 1.18 |
---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Fredun Pharmaceuticals Ltd operates in the pharmaceuticals industry, with its latest share price reported at ₹1,482 and a market capitalization of ₹700 Cr. The company has shown a significant upward trajectory in revenue, with sales rising from ₹222 Cr in FY 2022 to ₹275 Cr in FY 2023, and further projected at ₹456 Cr for FY 2025. The trailing twelve months (TTM) revenue stands at ₹497 Cr, indicating robust growth momentum. Quarterly sales have also demonstrated variability, with the highest quarterly revenue of ₹118.03 Cr recorded in March 2024, showcasing the company’s ability to scale operations effectively. The sales figures indicate a strong recovery following the dip to ₹62.05 Cr in June 2023, suggesting dynamic operational management amidst market fluctuations. The operational performance is further evidenced by the operating profit margin (OPM) of 14.18%, reflecting the company’s efficiency in managing operational costs while maximizing revenue generation.
Profitability and Efficiency Metrics
Fredun Pharmaceuticals has reported a net profit of ₹21 Cr for FY 2025, with an impressive earnings per share (EPS) of ₹44.07, indicating a strong capacity for profitability. The company has maintained a healthy return on equity (ROE) of 15.8% and a return on capital employed (ROCE) of 18.9%, which are benchmarks of effective capital utilization. The interest coverage ratio (ICR) is recorded at 2.46, suggesting that the company comfortably meets its interest obligations, though this is on the lower side compared to industry averages, indicating potential liquidity concerns. The cash conversion cycle (CCC) stands at 247 days, which is notably high, signaling potential inefficiencies in converting inventory and receivables into cash. This could indicate challenges in working capital management that need addressing. Overall, the profitability metrics are strong, but the efficiency ratios present areas for improvement.
Balance Sheet Strength and Financial Ratios
Fredun Pharmaceuticals’ balance sheet reflects a total borrowing of ₹166 Cr against reserves of ₹137 Cr, resulting in a debt-to-equity ratio of 1.18. This relatively high leverage may raise concerns regarding financial stability, particularly in an industry sensitive to regulatory changes and market volatility. The current ratio is reported at 1.31, suggesting adequate short-term liquidity, though the quick ratio of 0.57 indicates potential struggles in meeting immediate liabilities without liquidating inventory. The company’s total assets have increased significantly to ₹487 Cr, up from ₹257 Cr in FY 2023, indicating robust growth in asset base. The book value per share stands at ₹299.47, reflecting a solid equity foundation. However, the enterprise value of ₹477.26 Cr, in comparison to net operating revenue, indicates a valuation that may be on the higher side, suggesting that investors are pricing in future growth expectations.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Fredun Pharmaceuticals shows a stable structure with promoters holding 48.93% of the equity, down from previous highs, which may indicate a gradual dilution of control. Institutional investors hold a minimal stake, with domestic institutional investors (DIIs) at 1.59% and foreign institutional investors (FIIs) not reported, suggesting limited institutional interest. Public ownership stands at 49.49%, reflecting a diverse shareholder base with 7,906 total shareholders. This broad public participation can be a positive indicator of investor confidence in the company’s future prospects, despite the absence of significant institutional backing. Over the past reporting periods, the number of shareholders has increased, indicating growing interest among retail investors. However, the declining promoter stake may raise questions about long-term commitment, which could impact investor sentiment moving forward.
Outlook, Risks, and Final Insight
If margins sustain at current levels and operational efficiencies improve, Fredun Pharmaceuticals could leverage its growth trajectory to enhance profitability further. However, several risks loom, including the high cash conversion cycle, which could strain liquidity and operational flexibility. Additionally, the relatively high debt levels could pose challenges if market conditions deteriorate or if interest rates rise. The ongoing fluctuations in revenue and expenses necessitate a focused approach to cost management and inventory control. Furthermore, the dependency on domestic markets, coupled with limited institutional support, may restrict growth potential. Addressing these risks while capitalizing on operational strengths could position Fredun Pharmaceuticals favorably in the competitive pharmaceutical landscape. Continued monitoring of financial metrics and shareholder sentiment will be critical in assessing the company’s strategic direction and market performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Fredun Pharmaceuticals Ltd
Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
---|---|---|---|---|---|---|---|---|---|
Lactose (India) Ltd | 151 Cr. | 120 | 247/84.3 | 34.4 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
Gujarat Themis Biosyn Ltd | 4,993 Cr. | 458 | 465/192 | 112 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
Gujarat Terce Laboratories Ltd | 38.1 Cr. | 51.3 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
Gujarat Inject (Kerala) Ltd | 29.9 Cr. | 20.4 | 29.1/17.0 | 31.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
Industry Average | 20,038.24 Cr | 1,197.65 | 50.64 | 194.07 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 48.42 | 70.32 | 77.96 | 79.81 | 62.05 | 81.98 | 87.00 | 118.03 | 78.82 | 107.35 | 102.70 | 167.41 | 119.85 |
Expenses | 44.55 | 63.52 | 70.66 | 67.55 | 54.44 | 72.37 | 76.48 | 106.87 | 68.34 | 93.40 | 89.48 | 149.97 | 102.86 |
Operating Profit | 3.87 | 6.80 | 7.30 | 12.26 | 7.61 | 9.61 | 10.52 | 11.16 | 10.48 | 13.95 | 13.22 | 17.44 | 16.99 |
OPM % | 7.99% | 9.67% | 9.36% | 15.36% | 12.26% | 11.72% | 12.09% | 9.46% | 13.30% | 12.99% | 12.87% | 10.42% | 14.18% |
Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest | 1.91 | 1.86 | 1.95 | 3.55 | 2.61 | 2.90 | 3.77 | 4.37 | 3.91 | 5.31 | 5.00 | 8.15 | 6.53 |
Depreciation | 0.65 | 0.72 | 0.74 | 0.70 | 0.92 | 0.94 | 0.99 | 0.96 | 1.05 | 1.06 | 1.09 | 1.25 | 1.42 |
Profit before tax | 1.31 | 4.22 | 4.61 | 8.01 | 4.08 | 5.77 | 5.76 | 5.83 | 5.52 | 7.58 | 7.13 | 8.04 | 9.04 |
Tax % | 27.48% | 25.12% | 25.16% | 51.44% | 41.18% | 31.72% | 26.74% | 13.38% | 25.18% | 43.54% | 25.25% | 12.06% | 25.11% |
Net Profit | 0.94 | 3.15 | 3.46 | 3.89 | 2.40 | 3.94 | 4.22 | 5.06 | 4.13 | 4.27 | 5.33 | 7.07 | 6.77 |
EPS in Rs | 2.11 | 7.07 | 7.66 | 8.58 | 5.24 | 8.41 | 8.98 | 10.76 | 8.75 | 9.04 | 11.29 | 14.97 | 14.34 |
Last Updated: August 19, 2025, 3:29 pm
Below is a detailed analysis of the quarterly data for Fredun Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 119.85 Cr.. The value appears to be declining and may need further review. It has decreased from 167.41 Cr. (Mar 2025) to 119.85 Cr., marking a decrease of 47.56 Cr..
- For Expenses, as of Jun 2025, the value is 102.86 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 149.97 Cr. (Mar 2025) to 102.86 Cr., marking a decrease of 47.11 Cr..
- For Operating Profit, as of Jun 2025, the value is 16.99 Cr.. The value appears to be declining and may need further review. It has decreased from 17.44 Cr. (Mar 2025) to 16.99 Cr., marking a decrease of 0.45 Cr..
- For OPM %, as of Jun 2025, the value is 14.18%. The value appears strong and on an upward trend. It has increased from 10.42% (Mar 2025) to 14.18%, marking an increase of 3.76%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 6.53 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 8.15 Cr. (Mar 2025) to 6.53 Cr., marking a decrease of 1.62 Cr..
- For Depreciation, as of Jun 2025, the value is 1.42 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.25 Cr. (Mar 2025) to 1.42 Cr., marking an increase of 0.17 Cr..
- For Profit before tax, as of Jun 2025, the value is 9.04 Cr.. The value appears strong and on an upward trend. It has increased from 8.04 Cr. (Mar 2025) to 9.04 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.11%. The value appears to be increasing, which may not be favorable. It has increased from 12.06% (Mar 2025) to 25.11%, marking an increase of 13.05%.
- For Net Profit, as of Jun 2025, the value is 6.77 Cr.. The value appears to be declining and may need further review. It has decreased from 7.07 Cr. (Mar 2025) to 6.77 Cr., marking a decrease of 0.30 Cr..
- For EPS in Rs, as of Jun 2025, the value is 14.34. The value appears to be declining and may need further review. It has decreased from 14.97 (Mar 2025) to 14.34, marking a decrease of 0.63.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:20 am
Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 21 | 25 | 42 | 57 | 60 | 97 | 113 | 134 | 222 | 275 | 348 | 456 | 497 |
Expenses | 20 | 24 | 38 | 53 | 54 | 87 | 104 | 126 | 208 | 247 | 310 | 401 | 436 |
Operating Profit | 1 | 2 | 4 | 3 | 6 | 10 | 8 | 8 | 14 | 28 | 38 | 55 | 62 |
OPM % | 7% | 7% | 9% | 6% | 10% | 11% | 7% | 6% | 6% | 10% | 11% | 12% | 12% |
Other Income | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 0 | 0 |
Interest | 1 | 1 | 2 | 2 | 2 | 3 | 4 | 4 | 5 | 9 | 14 | 22 | 25 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 4 | 4 | 5 |
Profit before tax | 0 | 1 | 2 | 2 | 3 | 6 | 2 | 3 | 9 | 18 | 21 | 28 | 32 |
Tax % | 47% | 52% | 42% | 36% | 34% | 28% | 24% | 37% | 26% | 38% | 27% | 26% | |
Net Profit | 0 | 0 | 1 | 1 | 2 | 4 | 2 | 2 | 6 | 11 | 16 | 21 | 23 |
EPS in Rs | 1.02 | 1.11 | 4.55 | 6.08 | 5.11 | 11.18 | 4.76 | 5.04 | 14.30 | 23.85 | 33.22 | 44.07 | 49.64 |
Dividend Payout % | 0% | 0% | 13% | 10% | 12% | 6% | 14% | 14% | 5% | 3% | 2% | 2% |
YoY Net Profit Growth
Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
---|---|---|---|---|---|---|---|---|---|
YoY Net Profit Growth (%) | 0.00% | 100.00% | 100.00% | -50.00% | 0.00% | 200.00% | 83.33% | 45.45% | 31.25% |
Change in YoY Net Profit Growth (%) | 0.00% | 100.00% | 0.00% | -150.00% | 50.00% | 200.00% | -116.67% | -37.88% | -14.20% |
Fredun Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | 34% |
5 Years: | 32% |
3 Years: | 27% |
TTM: | 36% |
Compounded Profit Growth | |
---|---|
10 Years: | 54% |
5 Years: | 61% |
3 Years: | 49% |
TTM: | 35% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 41% |
3 Years: | 4% |
1 Year: | 64% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 13% |
3 Years: | 15% |
Last Year: | 16% |
Last Updated: September 5, 2025, 3:30 pm
Balance Sheet
Last Updated: July 25, 2025, 1:17 pm
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 2 | 2 | 2 | 2 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 |
Reserves | 0 | 0 | 1 | 2 | 19 | 35 | 37 | 39 | 64 | 92 | 117 | 137 |
Borrowings | 7 | 9 | 16 | 21 | 10 | 19 | 35 | 40 | 53 | 87 | 106 | 166 |
Other Liabilities | 8 | 11 | 24 | 30 | 47 | 47 | 65 | 79 | 66 | 74 | 81 | 179 |
Total Liabilities | 18 | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 |
Fixed Assets | 7 | 8 | 15 | 16 | 16 | 31 | 31 | 30 | 32 | 39 | 47 | 53 |
CWIP | 0 | 1 | 0 | 4 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
Other Assets | 11 | 14 | 29 | 36 | 52 | 74 | 110 | 131 | 155 | 218 | 260 | 433 |
Total Assets | 18 | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 |
Below is a detailed analysis of the balance sheet data for Fredun Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 5.00 Cr..
- For Reserves, as of Mar 2025, the value is 137.00 Cr.. The value appears strong and on an upward trend. It has increased from 117.00 Cr. (Mar 2024) to 137.00 Cr., marking an increase of 20.00 Cr..
- For Borrowings, as of Mar 2025, the value is 166.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 106.00 Cr. (Mar 2024) to 166.00 Cr., marking an increase of 60.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 179.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 81.00 Cr. (Mar 2024) to 179.00 Cr., marking an increase of 98.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 487.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 308.00 Cr. (Mar 2024) to 487.00 Cr., marking an increase of 179.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 53.00 Cr.. The value appears strong and on an upward trend. It has increased from 47.00 Cr. (Mar 2024) to 53.00 Cr., marking an increase of 6.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2024) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Mar 2025, the value is 433.00 Cr.. The value appears strong and on an upward trend. It has increased from 260.00 Cr. (Mar 2024) to 433.00 Cr., marking an increase of 173.00 Cr..
- For Total Assets, as of Mar 2025, the value is 487.00 Cr.. The value appears strong and on an upward trend. It has increased from 308.00 Cr. (Mar 2024) to 487.00 Cr., marking an increase of 179.00 Cr..
However, the Borrowings (166.00 Cr.) are higher than the Reserves (137.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | -6.00 | -7.00 | -12.00 | -18.00 | -4.00 | -9.00 | -27.00 | -32.00 | -39.00 | -59.00 | -68.00 | -111.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 59 | 75 | 98 | 131 | 94 | 67 | 126 | 112 | 148 | 46 | 68 | 142 |
Inventory Days | 107 | 102 | 140 | 68 | 170 | 249 | 227 | 242 | 96 | 264 | 246 | 265 |
Days Payable | 152 | 167 | 221 | 224 | 360 | 205 | 208 | 215 | 101 | 104 | 88 | 160 |
Cash Conversion Cycle | 14 | 11 | 17 | -24 | -96 | 110 | 145 | 139 | 144 | 205 | 225 | 247 |
Working Capital Days | -44 | -54 | -44 | -39 | 42 | 66 | 65 | 116 | 126 | 97 | 92 | 76 |
ROCE % | 14% | 14% | 25% | 18% | 16% | 21% | 10% | 10% | 13% | 18% | 17% | 19% |
This stock is not held by any mutual fund.
Key Financial Ratios
Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
---|---|---|---|---|---|
FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Basic EPS (Rs.) | 44.83 | 33.66 | 24.13 | 11.28 | 5.05 |
Diluted EPS (Rs.) | 44.83 | 33.32 | 22.93 | 11.28 | 5.05 |
Cash EPS (Rs.) | 53.49 | 41.32 | 30.04 | 19.16 | 10.07 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 299.47 | 258.49 | 212.64 | 153.54 | 107.96 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 299.47 | 258.49 | 212.64 | 153.54 | 107.96 |
Dividend / Share (Rs.) | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 |
Revenue From Operations / Share (Rs.) | 956.66 | 740.88 | 606.04 | 506.38 | 335.60 |
PBDIT / Share (Rs.) | 116.69 | 82.78 | 65.31 | 34.80 | 26.41 |
PBIT / Share (Rs.) | 107.27 | 74.70 | 59.11 | 29.93 | 21.39 |
PBT / Share (Rs.) | 59.87 | 45.65 | 38.63 | 19.40 | 8.04 |
Net Profit / Share (Rs.) | 44.07 | 33.25 | 23.84 | 14.29 | 5.05 |
PBDIT Margin (%) | 12.19 | 11.17 | 10.77 | 6.87 | 7.86 |
PBIT Margin (%) | 11.21 | 10.08 | 9.75 | 5.91 | 6.37 |
PBT Margin (%) | 6.25 | 6.16 | 6.37 | 3.83 | 2.39 |
Net Profit Margin (%) | 4.60 | 4.48 | 3.93 | 2.82 | 1.50 |
Return on Networth / Equity (%) | 14.71 | 12.86 | 11.21 | 9.30 | 4.67 |
Return on Capital Employeed (%) | 31.78 | 24.93 | 17.72 | 11.71 | 11.35 |
Return On Assets (%) | 4.27 | 5.07 | 4.20 | 3.38 | 1.24 |
Long Term Debt / Equity (X) | 0.06 | 0.10 | 0.50 | 0.61 | 0.67 |
Total Debt / Equity (X) | 1.18 | 0.86 | 0.89 | 0.77 | 0.92 |
Asset Turnover Ratio (%) | 1.14 | 1.23 | 1.24 | 1.29 | 0.90 |
Current Ratio (X) | 1.31 | 1.54 | 2.04 | 2.07 | 1.50 |
Quick Ratio (X) | 0.57 | 0.49 | 0.62 | 1.44 | 0.72 |
Inventory Turnover Ratio (X) | 1.56 | 1.75 | 2.51 | 3.11 | 1.71 |
Dividend Payout Ratio (NP) (%) | 0.00 | 2.09 | 2.88 | 4.89 | 13.30 |
Dividend Payout Ratio (CP) (%) | 0.00 | 1.68 | 2.28 | 3.65 | 6.67 |
Earning Retention Ratio (%) | 0.00 | 97.91 | 97.12 | 95.11 | 86.70 |
Cash Earning Retention Ratio (%) | 0.00 | 98.32 | 97.72 | 96.35 | 93.33 |
Interest Coverage Ratio (X) | 2.46 | 2.85 | 3.19 | 3.30 | 2.53 |
Interest Coverage Ratio (Post Tax) (X) | 1.93 | 2.14 | 2.16 | 2.36 | 1.76 |
Enterprise Value (Cr.) | 477.26 | 441.23 | 435.36 | 456.41 | 223.45 |
EV / Net Operating Revenue (X) | 1.06 | 1.27 | 1.59 | 2.03 | 1.67 |
EV / EBITDA (X) | 8.66 | 11.34 | 14.71 | 29.59 | 21.21 |
MarketCap / Net Operating Revenue (X) | 0.69 | 0.96 | 1.28 | 1.81 | 1.38 |
Retention Ratios (%) | 0.00 | 97.90 | 97.11 | 95.10 | 86.69 |
Price / BV (X) | 2.23 | 2.77 | 3.66 | 5.96 | 4.29 |
Price / Net Operating Revenue (X) | 0.69 | 0.96 | 1.28 | 1.81 | 1.38 |
EarningsYield | 0.06 | 0.04 | 0.03 | 0.01 | 0.01 |
After reviewing the key financial ratios for Fredun Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 44.83. This value is within the healthy range. It has increased from 33.66 (Mar 24) to 44.83, marking an increase of 11.17.
- For Diluted EPS (Rs.), as of Mar 25, the value is 44.83. This value is within the healthy range. It has increased from 33.32 (Mar 24) to 44.83, marking an increase of 11.51.
- For Cash EPS (Rs.), as of Mar 25, the value is 53.49. This value is within the healthy range. It has increased from 41.32 (Mar 24) to 53.49, marking an increase of 12.17.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.47. It has increased from 258.49 (Mar 24) to 299.47, marking an increase of 40.98.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.47. It has increased from 258.49 (Mar 24) to 299.47, marking an increase of 40.98.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.70. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.70.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 956.66. It has increased from 740.88 (Mar 24) to 956.66, marking an increase of 215.78.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 116.69. This value is within the healthy range. It has increased from 82.78 (Mar 24) to 116.69, marking an increase of 33.91.
- For PBIT / Share (Rs.), as of Mar 25, the value is 107.27. This value is within the healthy range. It has increased from 74.70 (Mar 24) to 107.27, marking an increase of 32.57.
- For PBT / Share (Rs.), as of Mar 25, the value is 59.87. This value is within the healthy range. It has increased from 45.65 (Mar 24) to 59.87, marking an increase of 14.22.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 44.07. This value is within the healthy range. It has increased from 33.25 (Mar 24) to 44.07, marking an increase of 10.82.
- For PBDIT Margin (%), as of Mar 25, the value is 12.19. This value is within the healthy range. It has increased from 11.17 (Mar 24) to 12.19, marking an increase of 1.02.
- For PBIT Margin (%), as of Mar 25, the value is 11.21. This value is within the healthy range. It has increased from 10.08 (Mar 24) to 11.21, marking an increase of 1.13.
- For PBT Margin (%), as of Mar 25, the value is 6.25. This value is below the healthy minimum of 10. It has increased from 6.16 (Mar 24) to 6.25, marking an increase of 0.09.
- For Net Profit Margin (%), as of Mar 25, the value is 4.60. This value is below the healthy minimum of 5. It has increased from 4.48 (Mar 24) to 4.60, marking an increase of 0.12.
- For Return on Networth / Equity (%), as of Mar 25, the value is 14.71. This value is below the healthy minimum of 15. It has increased from 12.86 (Mar 24) to 14.71, marking an increase of 1.85.
- For Return on Capital Employeed (%), as of Mar 25, the value is 31.78. This value is within the healthy range. It has increased from 24.93 (Mar 24) to 31.78, marking an increase of 6.85.
- For Return On Assets (%), as of Mar 25, the value is 4.27. This value is below the healthy minimum of 5. It has decreased from 5.07 (Mar 24) to 4.27, marking a decrease of 0.80.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.10 (Mar 24) to 0.06, marking a decrease of 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.18. This value exceeds the healthy maximum of 1. It has increased from 0.86 (Mar 24) to 1.18, marking an increase of 0.32.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.14. It has decreased from 1.23 (Mar 24) to 1.14, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 1.5. It has decreased from 1.54 (Mar 24) to 1.31, marking a decrease of 0.23.
- For Quick Ratio (X), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 1. It has increased from 0.49 (Mar 24) to 0.57, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.56. This value is below the healthy minimum of 4. It has decreased from 1.75 (Mar 24) to 1.56, marking a decrease of 0.19.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 2.09 (Mar 24) to 0.00, marking a decrease of 2.09.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 1.68 (Mar 24) to 0.00, marking a decrease of 1.68.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 97.91 (Mar 24) to 0.00, marking a decrease of 97.91.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 98.32 (Mar 24) to 0.00, marking a decrease of 98.32.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 3. It has decreased from 2.85 (Mar 24) to 2.46, marking a decrease of 0.39.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.93. This value is below the healthy minimum of 3. It has decreased from 2.14 (Mar 24) to 1.93, marking a decrease of 0.21.
- For Enterprise Value (Cr.), as of Mar 25, the value is 477.26. It has increased from 441.23 (Mar 24) to 477.26, marking an increase of 36.03.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 1.27 (Mar 24) to 1.06, marking a decrease of 0.21.
- For EV / EBITDA (X), as of Mar 25, the value is 8.66. This value is within the healthy range. It has decreased from 11.34 (Mar 24) to 8.66, marking a decrease of 2.68.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has decreased from 0.96 (Mar 24) to 0.69, marking a decrease of 0.27.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 97.90 (Mar 24) to 0.00, marking a decrease of 97.90.
- For Price / BV (X), as of Mar 25, the value is 2.23. This value is within the healthy range. It has decreased from 2.77 (Mar 24) to 2.23, marking a decrease of 0.54.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has decreased from 0.96 (Mar 24) to 0.69, marking a decrease of 0.27.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.06, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fredun Pharmaceuticals Ltd:
- Net Profit Margin: 4.6%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 31.78% (Industry Average ROCE: 16.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 14.71% (Industry Average ROE: 14.47%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.93
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.57
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 33.4 (Industry average Stock P/E: 42.06)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.18
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.6%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Pharmaceuticals | URMI ESTATE, 11th Floor, Mumbai Maharashtra 400013 | business@fredungroup.com http://www.fredungroup.com |
Management | |
---|---|
Name | Position Held |
Dr.(Mrs.) Daulat N Medhora | Chairman & Jt. M. D |
Mr. Fredun Medhora | Managing Director & CFO |
Mr. Nariman Medhora | Non Executive Director |
Dr. Rohinton Kanga | Ind. Non-Executive Director |
Dr. Aspi Raimalwala | Ind. Non-Executive Director |
Mrs. Daisy D�souza | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Fredun Pharmaceuticals Ltd?
Fredun Pharmaceuticals Ltd's intrinsic value (as of 23 October 2025) is 1262.81 which is 23.97% lower the current market price of 1,661.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 784 Cr. market cap, FY2025-2026 high/low of 1,682/635, reserves of ₹137 Cr, and liabilities of 487 Cr.
What is the Market Cap of Fredun Pharmaceuticals Ltd?
The Market Cap of Fredun Pharmaceuticals Ltd is 784 Cr..
What is the current Stock Price of Fredun Pharmaceuticals Ltd as on 23 October 2025?
The current stock price of Fredun Pharmaceuticals Ltd as on 23 October 2025 is 1,661.
What is the High / Low of Fredun Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fredun Pharmaceuticals Ltd stocks is 1,682/635.
What is the Stock P/E of Fredun Pharmaceuticals Ltd?
The Stock P/E of Fredun Pharmaceuticals Ltd is 33.4.
What is the Book Value of Fredun Pharmaceuticals Ltd?
The Book Value of Fredun Pharmaceuticals Ltd is 299.
What is the Dividend Yield of Fredun Pharmaceuticals Ltd?
The Dividend Yield of Fredun Pharmaceuticals Ltd is 0.04 %.
What is the ROCE of Fredun Pharmaceuticals Ltd?
The ROCE of Fredun Pharmaceuticals Ltd is 18.9 %.
What is the ROE of Fredun Pharmaceuticals Ltd?
The ROE of Fredun Pharmaceuticals Ltd is 15.8 %.
What is the Face Value of Fredun Pharmaceuticals Ltd?
The Face Value of Fredun Pharmaceuticals Ltd is 10.0.